Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Yang

Showing results (511-520 of 566) with videos related to

Pageof 57
Sort By:
Scientific Reports|October 16, 2015
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized TrialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Cancer Research|July 17, 2019
SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell QuiescenceSen Ye, Yan-Fu Ding, Wen-Huan Jia, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Scientific Reports|September 5, 2020
Genome-wide association study for circulating fibroblast growth factor 21 and 23Gwo-Tsann Chuang, Pi-Hua Liu, Tsui-Wei Chyan, et al.
Scientific Reports|September 14, 2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational studyChen-Hua Liu, Yi-Jie Huang, Sien-Sing Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Journal of the National Cancer Institute|September 22, 2005
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphomaLi-Tzong Chen, Jaw-Town Lin, John Jen Tai, et al.
Medicine|September 30, 2016
A nationwide survey of clinical characteristics, management, and outcomes of acute kidney injury (AKI) - patients with and without preexisting chronic kidney disease have different prognosesHeng-Chih Pan, Pei-Chen Wu, Vin-Cent Wu, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Pageof 57

Showing results (511-520 of 566) with videos related to

Sort By:
Pageof 57
Scientific Reports|October 16, 2015
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized TrialChen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, et al.
Cancer Research|July 17, 2019
SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell QuiescenceSen Ye, Yan-Fu Ding, Wen-Huan Jia, et al.
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Scientific Reports|September 5, 2020
Genome-wide association study for circulating fibroblast growth factor 21 and 23Gwo-Tsann Chuang, Pi-Hua Liu, Tsui-Wei Chyan, et al.
Scientific Reports|September 14, 2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational studyChen-Hua Liu, Yi-Jie Huang, Sien-Sing Yang, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2025
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus InfectionYu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, et al.
Journal of the National Cancer Institute|September 22, 2005
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphomaLi-Tzong Chen, Jaw-Town Lin, John Jen Tai, et al.
Medicine|September 30, 2016
A nationwide survey of clinical characteristics, management, and outcomes of acute kidney injury (AKI) - patients with and without preexisting chronic kidney disease have different prognosesHeng-Chih Pan, Pei-Chen Wu, Vin-Cent Wu, et al.
Journal of Medical Virology|May 15, 2024
Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Ji-Yuh Lee, et al.
Pageof 57